664 related articles for article (PubMed ID: 23103355)
21. Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells.
Gonçalves P; Araújo JR; Azevedo I; Martel F
Pharmacology; 2008; 82(1):30-7. PubMed ID: 18431074
[TBL] [Abstract][Full Text] [Related]
22. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
23. The role of the endogenous cannabinoid system in peripheral analgesia.
Guindon J; Beaulieu P
Curr Mol Pharmacol; 2009 Jan; 2(1):134-9. PubMed ID: 20021453
[TBL] [Abstract][Full Text] [Related]
24. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
Gustafsson SB; Lindgren T; Jonsson M; Jacobsson SO
Cancer Chemother Pharmacol; 2009 Mar; 63(4):691-701. PubMed ID: 18629502
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death.
Athanasiou A; Clarke AB; Turner AE; Kumaran NM; Vakilpour S; Smith PA; Bagiokou D; Bradshaw TD; Westwell AD; Fang L; Lobo DN; Constantinescu CS; Calabrese V; Loesch A; Alexander SP; Clothier RH; Kendall DA; Bates TE
Biochem Biophys Res Commun; 2007 Dec; 364(1):131-7. PubMed ID: 17931597
[TBL] [Abstract][Full Text] [Related]
27. Endocannabinoids and the gut.
Pinto L; Capasso R; Di Carlo G; Izzo AA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):333-41. PubMed ID: 12052047
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines.
Miyato H; Kitayama J; Yamashita H; Souma D; Asakage M; Yamada J; Nagawa H
J Surg Res; 2009 Jul; 155(1):40-7. PubMed ID: 19394652
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid receptors and their ligands.
Pertwee RG; Ross RA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
[TBL] [Abstract][Full Text] [Related]
31. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
Barana A; Amorós I; Caballero R; Gómez R; Osuna L; Lillo MP; Blázquez C; Guzmán M; Delpón E; Tamargo J
Cardiovasc Res; 2010 Jan; 85(1):56-67. PubMed ID: 19689982
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
Olea-Herrero N; Vara D; Malagarie-Cazenave S; Díaz-Laviada I
Br J Cancer; 2009 Sep; 101(6):940-50. PubMed ID: 19690545
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
34. Endocannabinoids as cardiovascular modulators.
Kunos G; Járai Z; Bátkai S; Goparaju SK; Ishac EJ; Liu J; Wang L; Wagner JA
Chem Phys Lipids; 2000 Nov; 108(1-2):159-68. PubMed ID: 11106789
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular effects of endocannabinoids--the plot thickens.
Kunos G; Járai Z; Varga K; Liu J; Wang L; Wagner JA
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):71-84. PubMed ID: 10785543
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoids and brain injury: therapeutic implications.
Mechoulam R; Panikashvili D; Shohami E
Trends Mol Med; 2002 Feb; 8(2):58-61. PubMed ID: 11815270
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.
Hiley CR; Ford WR
Biol Rev Camb Philos Soc; 2004 Feb; 79(1):187-205. PubMed ID: 15005177
[TBL] [Abstract][Full Text] [Related]
38. Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis.
Coopman K; Smith LD; Wright KL; Ward SG
Int Immunopharmacol; 2007 Mar; 7(3):360-71. PubMed ID: 17276894
[TBL] [Abstract][Full Text] [Related]
39. Endocannabinoids and the heart.
Hiley CR
J Cardiovasc Pharmacol; 2009 Apr; 53(4):267-76. PubMed ID: 19276990
[TBL] [Abstract][Full Text] [Related]
40. The cannabinoid system and cytokine network.
Klein TW; Lane B; Newton CA; Friedman H
Proc Soc Exp Biol Med; 2000 Oct; 225(1):1-8. PubMed ID: 10998193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
